Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

5.5K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
5.5K
Cancer Vaccines01:30

Cancer Vaccines

1.4K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.4K
Cancer Survival Analysis01:21

Cancer Survival Analysis

843
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
843
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

5.1K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chronic obstructive pulmonary disease: diagnosis, monitoring and chronic management in nursing practice.

British journal of nursing (Mark Allen Publishing)·2026
Same author

Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trial.

Cell reports. Medicine·2026
Same author

The path forward for T cell engagers in patients with prostate cancer.

Journal for immunotherapy of cancer·2026
Same author

Estimating the long-term health outcomes of treatment with lecanemab in early Alzheimer's disease: a modelling study.

Journal of medical economics·2026
Same author

Implementation of a Multihospital Electronic Medical Record-Based Insulin Order Set to Reduce Hypoglycemic Events.

AACE endocrinology and diabetes·2025
Same author

Predictors of Long-Term Disease-Free Survival With Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer.

International journal of radiation oncology, biology, physics·2025
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
See all related articles

Related Experiment Video

Updated: Apr 10, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

Prostate cancer.

Gerhardt Attard1, Chris Parker2, Ros A Eeles3

  • 1Division of Clinical Studies, The Institute of Cancer Research, London, UK; Prostate Cancer Targeted Therapy Group, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK.

Lancet (London, England)
|June 16, 2015
PubMed
Summary
This summary is machine-generated.

Recent prostate cancer research advances genetic understanding for targeted screening and identifies molecular subtypes for personalized treatment. Survival for metastatic disease has improved, but optimal sequencing of new therapies requires further study.

More Related Videos

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.3K
Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

15.3K

Related Experiment Videos

Last Updated: Apr 10, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.3K
Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

15.3K

Area of Science:

  • Oncology
  • Genetics
  • Translational Research

Background:

  • Prostate cancer research has advanced significantly in the last decade.
  • Greater understanding of the genetic basis of familial prostate cancer, including high-risk mutations (e.g., BRCA2, HOXB13) and common low-risk alleles, aids in identifying at-risk individuals.
  • Current prostate cancer screening using prostate-specific antigen (PSA) is controversial due to overdiagnosis and unnecessary biopsies, despite reducing mortality.

Purpose of the Study:

  • To review recent progress in prostate cancer research, focusing on genetic discoveries, molecular subtyping, and therapeutic advancements.
  • To highlight the challenges in managing localized and metastatic prostate cancer, particularly castration-resistant prostate cancer (CRPC).
  • To emphasize the urgent need for further clinical and translational research to personalize prostate cancer management.

Main Methods:

  • Review of recent scientific literature and clinical trial data in prostate cancer research.
  • Analysis of genetic findings, including genome-wide association studies (GWAS) and familial mutation identification.
  • Evaluation of therapeutic strategies for localized and metastatic prostate cancer, including CRPC treatments.

Main Results:

  • Identification of key genetic mutations (e.g., BRCA2, HOXB13) and common alleles for targeted screening.
  • Classification of prostate cancer into molecular subtypes (e.g., ETS-gene-fusion-positive, SPINK1-overexpressing, CHD1-loss) for potential patient stratification.
  • Substantial improvements in survival for metastatic castration-resistant prostate cancer (mCRPC) with the advent of five new drugs in addition to docetaxel.

Conclusions:

  • Advances in genetics and molecular subtyping offer potential for more personalized prostate cancer screening and management.
  • While survival for mCRPC has improved, optimal treatment selection and sequencing remain challenging due to a lack of robust data and high drug costs.
  • Continued clinical and translational research is crucial for improving and personalizing prostate cancer care.